Nektar Therapeutics

Nektar Therapeutics

Nektar Therapeutics

Overview
Date Founded

1998

Headquarters

455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158

Type of Company

Public

Employees (Worldwide)

618

Industries

Biotechnology
Hospitals & Patient Services
Pharmaceuticals

Company Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Contact Data
Trying to get in touch with decision makers at Nektar Therapeutics? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Senior Vice President & Chief Financial Officer

Senior Vice President & Chief Operating Officer

Secretary, Senior Vice President & General Counsel

Senior Vice President, Research & Chief Scientific Officer

Senior Vice President, Clinical Development & Chief Medical Officer

Senior Vice President, Finance & Chief Accounting Officer

Chief Technical Operations Officer

Vice President & Head of Discovery & Research

Senior Vice President, Clinical Development & Head of Nektar's Immunology Program

Board of Directors

Chairman at Biota Technology, Inc.

Founder at Numenor Ventures LLC

Professional at Veracyte, Inc.

President & Chief Executive Officer at Nektar Therapeutics

Professional at Nektar Therapeutics

Former Vice President-Global Transplant Operations at Genzyme Corp.

Professional at Nektar Therapeutics

Paths to Nektar Therapeutics
Potential Connections via
Relationship Science
You
Nektar Therapeutics
Owners & Shareholders
Details Hidden

PRIMECAP invests primarily common stocks or securities with common stock characteristics, bonds and cash/cash equivalents. The firm utilizes fundamental research and bottom-up stock picking to construct portfolios. The main sources of information for research purposes include financial publications, inspections of corporate activities, research materials by others such as sell-side analysts, companies' annual reports and any related filings and press releases, meetings with executives of companies and their suppliers, competitors, customers, etc. All portfolios are built with the best ideas of each of the managers within the multi-manager investment process. PRIMECAP's investment strategy does not employ short sales or margin transactions, nor does it permit investments in derivatives or currency hedging. The firm follows an investment approach based on four key principles including commitment to fundamental research, long-term investment horizon, emphasis on individual decision-making and focus on value.

Details Hidden

Camber Capital Management seeks to generate capital appreciation without regard to current income. They seek to achieve this objective by investing primarily in publicly-traded common stocks of healthcare companies across a variety of industries including healthcare services and facilities, pharmaceuticals, medical products and devices and biotechnology. Although most of their investments are within the healthcare industry, Camber may occasionally invest in other sectors if more attractive opportunities are identified.Camber employs a fundamental, bottom-up research approach designed to identify high-quality companies whose inherent value is not adequately reflected in a company's market valuation. The firm believes that the excessive focus on short-term returns and near term catalysts within the healthcare space often causes public market prices to greatly overreact to near term news flow. Camber takes on short-term risk in order to capitalize on attractive intermediate- to long-term opportunities. To maximize returns, they may, on occasion, employ the use of leverage.

Details Hidden

Bridger Management manages various pooled investment funds whose primary investment objective is to achieve long-term, risk-adjusted capital growth generally through investments in equity securities and equity related instruments, with emphasis on publicly traded securities.Bridger seeks to acquire long positions in companies where they have identified fundamental value drivers that have not been recognized or fully exploited by the broader investment community. Long positions typically consist of investments in companies whose growth prospects demonstrate significant potential for high incremental returns on investment, with well-defined competitive advantages. Such advantages may include high barriers to entry, large market opportunities and strong management teams. They may also seek to acquire long positions in companies whose valuation reflects a disproportionate discount to its private market value or peer group, where they have identified a catalyst for capital appreciation. These catalysts may include a restructuring, spin-off or change in management control.Bridger believes that short positions not only serve as a hedge against volatile market conditions, but also generate profit opportunities for the clients. Because of the risks inherent in short selling, the firm devotes significant effort to generating short ideas through their field research and proprietary screens. Bridger may seek to acquire a short position when they determine that the investment community has a fundamental misperception about a company's business prospects and they have identified a timeline and catalyst for a correction in valuation. Such catalysts may include product failures, customer losses or overestimated market potential. Short positions may also be taken in companies with balance sheets that reflect significant business risk. Such companies may have deteriorating fundamentals, poor cash generation capabilities and reliance on debt financing. Bridger may seek to acquire securities of non-U.S. issuers and a variety of fixed income and equity or equity related instruments, including swaps, options, futures and forward contracts, as well as any other instruments (such as private investment funds managed by third party investment managers). The firm may use leveraging and hedging techniques to seek to maximize returns and minimize risk.

Recent Transactions
Details Hidden

Nektar Therapeutics issued USD Common Stock

Details Hidden

Nektar Therapeutics issued Common Stock

Details Hidden

Nektar Therapeutics issued Common Stock

Transaction Advisors
Accountant

Advised onNektar Therapeutics purchases Shearwater Corp.

Underwriter

Advised onNektar Therapeutics issued USD Common Stock

Underwriter

Advised onNektar Therapeutics issued USD Common Stock

Legal Advisor

Advised onNektar Therapeutics issued Common Stock

Legal Advisor

Advised onNektar Therapeutics issued Common Stock

Head, Healthcare Investment Banking

Advised onNektar Therapeutics issued Common Stock

Advisors & Consultants
Legal Advisor

Partner, San Diego at Cooley LLP

Advisor

Former Chief Technical Operations Officer at Nektar Therapeutics

Legal Advisor

Partner at Cadwalader, Wickersham & Taft LLP

Clients

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Key Stats and Financials As of 2018
Market Capitalization
$6.06B
Total Enterprise Value
$4.89B
Earnings Per Share
$3.78
Revenue
$1.19B
EBITDAMargin
58.39%
Enterprise Value Sales
4.1x
TEVNet Income
7.18x
Debt TEV
0.06x
Net Profit
$681M
EBITDA
$697M
Total Equity
$1.72B
Total Debt
$309M
Three Year Compounded Annual Growth Rate Of Revenue
72.92%
Five Year Compounded Annual Growth Rate Of Revenue
51.62%
Enterprise Value EBITDAOperating
7.02x
Non-Profit Donations & Grants
Political Donations
$6,500
2012
Investments
Details Hidden

Pearl Therapeutics, Inc. develops therapies for the treatment of chronic respiratory diseases. It offers respiratory product development, high quality therapies for COPD, Asthma and treatment and prevention of chronic respiratory diseases and asthma. The company was founded in 2006 by Sarvajna Dwivedi and is headquartered in Redwood City, CA.

Investors
Details Hidden

AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 6012, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Suppliers
Enzon Pharmaceuticals Inc. Industrial Machinery & Manufacturing | Piscataway, NJ

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company was founded on September 17, 1981 and is headquartered in Cranford, NJ.

Johnson Matthey Plc Industrial Machinery & Manufacturing | LONDON, GL

A leader in sustainable technologies, many of the group’s products enhance the quality of life of millions through their beneficial impact on the environment, human health and wellbeing. The world has changed a lot since Johnson Matthey’s foundation in 1817. From its early days as a precious metals assayer, the company has always sought to build on its strengths and respond to changing global needs. Today the group continues to apply its expertise in science and innovation to develop world leading products and technologies for customers around the world. What we Do We focus on clean air, clean energy and low carbon technologies and are experts in the application and recycling of precious metals. Our principal activities are: Manufacturing autocatalysts, heavy duty diesel catalysts and pollution control systems Providing catalysts and components for fuel cells Supplying catalysts and technologies for chemical processes Producing fine chemicals, chemical catalysts and active pharmaceutical ingredients Marketing, refining and fabricating precious metals. Johnson Matthey has operations in over 30 countries and employs around 10,000 people. Our products and services are sold across the world to a wide range of advanced technology industries

ImaginAb, Inc. Medical Support Services | INGLEWOOD , CA

ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Bausch Health Cos., Inc. Pharmaceuticals - Laval, QC

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Dr Reddy's Laboratories Ltd. Pharmaceuticals - Hyderabad, TS

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The Global Generics segment is consist of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The PSAI segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Nektar Therapeutics. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Nektar Therapeutics's profile does not indicate a business or promotional relationship of any kind between RelSci and Nektar Therapeutics.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/nektar-therapeutics-18798
  • https://relationshipscience.com/organization/nektar-therapeutics-18798